Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy
Status:
Terminated
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
In order to optimize anti-cytomegalovirus (CMV) treatment with ganciclovir (GCV), in patients
with multi organ failure treated with continuous renal replacement therapy (RRT), more
information about ganciclovir pharmacokinetics in this setting is needed.
The primary objective is to describe the pharmacokinetics of ganciclovir in critically ill
patients with acute renal failure treated with continuous renal replacement therapy, with a
special emphasis on the extra-renal clearance and distribution volume.
Secondary objectives are to investigate if any co-factors, such as serum creatinine, weight,
general hydration status, rest function of the native kidneys, etc. can help to describe the
pharmacokinetics of GCV in these patients on continuous RRT as well as the relative influence
of filtrations and dialysis on GCV elimination during different modalities of the treatment.